Literature DB >> 22369072

Fifty years after thalidomide; what role for drug regulators?

Hans-Georg Eichler, Eric Abadie, Mary Baker, Guido Rasi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22369072      PMCID： PMC3495136          DOI： 10.1111/j.1365-2125.2012.04255.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  2 in total

1.  Balancing the benefits and risks of inhaled long-acting beta-agonists--the influence of values.

Authors:  Judith M Kramer
Journal:  N Engl J Med       Date:  2009-04-16       Impact factor: 91.245

2.  Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran.

Authors:  B Nhi Beasley; Ellis F Unger; Robert Temple
Journal:  N Engl J Med       Date:  2011-04-13       Impact factor: 91.245
  2 in total
  7 in total

Review 1.  The risks of risk aversion in drug regulation.

Authors:  Hans-Georg Eichler; Brigitte Bloechl-Daum; Daniel Brasseur; Alasdair Breckenridge; Hubert Leufkens; June Raine; Tomas Salmonson; Christian K Schneider; Guido Rasi
Journal:  Nat Rev Drug Discov       Date:  2013-11-15       Impact factor: 84.694

Review 2.  Pharmaceutical Benefit-Risk Communication Tools: A Review of the Literature.

Authors:  Dominic Way; Hortense Blazsin; Ragnar Löfstedt; Frederic Bouder
Journal:  Drug Saf       Date:  2017-01       Impact factor: 5.606

3.  Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies.

Authors:  Lourens T Bloem; Rick A Vreman; Niels W L Peeters; Jarno Hoekman; Menno E van der Elst; Hubert G M Leufkens; Olaf H Klungel; Wim G Goettsch; Aukje K Mantel-Teeuwisse
Journal:  Clin Transl Sci       Date:  2021-05-01       Impact factor: 4.689

4.  Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers.

Authors:  T Morel; S Aymé; D Cassiman; S Simoens; M Morgan; M Vandebroek
Journal:  Orphanet J Rare Dis       Date:  2016-05-26       Impact factor: 4.123

5.  Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review.

Authors:  Rosanne Janssens; Isabelle Huys; Eline van Overbeeke; Chiara Whichello; Sarah Harding; Jürgen Kübler; Juhaeri Juhaeri; Antonio Ciaglia; Steven Simoens; Hilde Stevens; Meredith Smith; Bennett Levitan; Irina Cleemput; Esther de Bekker-Grob; Jorien Veldwijk
Journal:  BMC Med Inform Decis Mak       Date:  2019-10-04       Impact factor: 2.796

6.  From Individual to Population Preferences: Comparison of Discrete Choice and Dirichlet Models for Treatment Benefit-Risk Tradeoffs.

Authors:  Tommi Tervonen; Francesco Pignatti; Douwe Postmus
Journal:  Med Decis Making       Date:  2019-09-09       Impact factor: 2.583

7.  The Patient Perspective: A Matter of Minutes.

Authors:  Rocco Falchetto
Journal:  Patient       Date:  2020-02       Impact factor: 3.883
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.